669 related articles for article (PubMed ID: 15364135)
1. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
2. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC
Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915
[TBL] [Abstract][Full Text] [Related]
4. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
[TBL] [Abstract][Full Text] [Related]
5. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
Bonnesen B; Pappot H; Holmstav J; Skov BG
Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
[TBL] [Abstract][Full Text] [Related]
7. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer.
Kawasaki M; Nakanishi Y; Kuwano K; Yatsunami J; Takayama K; Hara N
Clin Cancer Res; 1997 Jul; 3(7):1195-200. PubMed ID: 9815799
[TBL] [Abstract][Full Text] [Related]
8. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
9. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.
Boku N; Chin K; Hosokawa K; Ohtsu A; Tajiri H; Yoshida S; Yamao T; Kondo H; Shirao K; Shimada Y; Saito D; Hasebe T; Mukai K; Seki S; Saito H; Johnston PG
Clin Cancer Res; 1998 Jun; 4(6):1469-74. PubMed ID: 9626464
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Uchida Y
Cancer; 2003 Jan; 97(2):457-64. PubMed ID: 12518370
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer.
Liu H; Zhang T; Li X; Huang J; Wu B; Huang X; Zhou Y; Zhu J; Hou J
Cancer Sci; 2008 Nov; 99(11):2185-92. PubMed ID: 18823373
[TBL] [Abstract][Full Text] [Related]
12. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
Miyatake K; Gemba K; Ueoka H; Nishii K; Kiura K; Tabata M; Shibayama T; Takigawa N; Kawaraya M; Tanimoto M
Anticancer Res; 2003; 23(3C):2829-36. PubMed ID: 12926120
[TBL] [Abstract][Full Text] [Related]
14. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
15. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
Jeong SH; Jung JH; Han JH; Kim JH; Choi YW; Lee HW; Kang SY; Hwang YH; Ahn MS; Choi JH; Oh YT; Chun M; Kang S; Park KJ; Hwang SC; Sheen SS
Lung Cancer; 2010 May; 68(2):288-94. PubMed ID: 19560836
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer.
Shibata Y; Hidaka S; Tagawa Y; Nagayasu T
Anticancer Res; 2004; 24(3b):1925-8. PubMed ID: 15274378
[TBL] [Abstract][Full Text] [Related]
17. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.
Giatromanolaki A; Koukourakis M; Zaramboukas T; Skordalaki A; Arapantoni P; Georgoulias V; Fountzilas G
Anticancer Res; 1998; 18(6B):4685-92. PubMed ID: 9891541
[TBL] [Abstract][Full Text] [Related]
18. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer.
Borner MM; Brousset P; Pfanner-Meyer B; Bacchi M; Vonlanthen S; Hotz MA; Altermatt HJ; Schlaifer D; Reed JC; Betticher DC
Br J Cancer; 1999 Feb; 79(5-6):952-8. PubMed ID: 10070896
[TBL] [Abstract][Full Text] [Related]
19. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
